Lesheng Pharmaceutical

Lesheng Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the development of innovative small molecule drugs for autoimmune diseases and oncology. The company's core focus is on the Janus kinase (JAK) signaling pathway, with its lead candidate, LS-001, being a highly selective Janus kinase 1 (JAK1) inhibitor currently in Phase 2 clinical trials for indications such as atopic dermatitis and rheumatoid arthritis. Lesheng leverages its drug discovery expertise to design molecules with superior selectivity and safety profiles to minimize off-target effects common in first-generation inhibitors. Based in the BioBAY industrial park, the company is supported by prominent regional investors and aims to provide high-quality therapeutic options for patients with chronic inflammatory conditions.